Skip to main content
Premium Trial:

Request an Annual Quote

InformedDNA to Offer Phenomix Sciences' Obesity Test

NEW YORK — Precision health and telegenetics firm InformedDNA has struck a deal to offer Phenomix Sciences' MyPhenome genetic obesity test to its customers, the companies said on Thursday.

The MyPhenome saliva test, which is based on technology Phenomix licensed from the Mayo Clinic in mid-2021, uses genetic and other biomarkers to identify four obesity phenotypes: Hungry Brain, a defect of satiation; Hungry Gut, a defect of satiety; Emotional Hunger, emotional reward from eating; and Slow Burn, inefficient metabolism. The categories are meant to help doctors personalize obesity treatment plans, including prescribing GLP-1 agonists like Novo Nordisk's Ozempic (semaglutide).

Menlo Park, California-based Phenomix launched the test earlier this year, shortly before closing a $5.5 million Series A funding round.

Under the terms of the deal, InformedDNA will incorporate MyPhenome into its DNAimpact product, its precision health platform that includes genetic test ordering support and consultations with genetic counselors.

Financial and other terms of the deal were not disclosed.

About a year ago, InformedDNA acquired digital health company gWell Health and appointed that company's founder as its new CEO. More recently, the St. Petersburg, Florida-based firm agreed to offer genetic counseling services through a genetic testing program offered by the Foundation Fighting Blindness.